ID | 116741 |
Title Alternative | lenvatinib in nonviral hepatocarcinoma
|
Author |
Tomonari, Tetsu
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Mitsuhashi, Takeshi
Tokushima University
Tanaka, Takahiro
Tokushima University
Okamoto, Koichi
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Sogabe, Masahiro
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Miyamoto, Hiroshi
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
|
Keywords | atezolizumab
bevacizumab
lenvatinib
|
Content Type |
Journal Article
|
Description | Aim: To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC).
Methods and Results: Sixty-seven patients with unresectable advanced HCC (u-HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepatitis B virus (HBV), 11 alcohol, and 11 nonalcoholic steatohepatitis (NASH) cases were retrospectively recruited. Univariate and multivariate Cox proportional hazard models were used to determine predictive factors for survival. The objective response rate in the nonviral (alcohol and NASH) group was higher than that in the viral group (59.1% [13/22] vs. 46.7% [21/45]). Progression-free survival was significantly longer in the nonviral group than in the viral group (13.7 vs. 6.6 months; hazard ratio [HR] 0.324; 95% confidence interval [CI] 0.174–0.602; P < 0.01). Similarly, median overall survival (OS) was significantly longer in the nonviral group than in the viral group (not evaluable vs. 15.9 months; HR = 0.277; 95% CI = 0.116–0.662; P < 0.01). Multivariate analysis revealed that portal vein invasion (HR = 5.327, P = 0.0025), treatment line (HR = 0.455, P = 0.023), and etiology (HR = 0.180, P = 0.00055) were significant independent factors associated with OS in u-HCC patients treated with LEN. Conclusion: Our results suggest that LEN is more effective against nonviral u-HCC than against viral u-HCC. |
Journal Title |
JGH Open
|
ISSN | 23979070
|
Publisher | Journal of Gastroenterology and Hepatology Foundation|John Wiley & Sons Australia
|
Volume | 5
|
Issue | 11
|
Start Page | 1275
|
End Page | 1283
|
Published Date | 2021-10-22
|
Rights | This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
University Hospital
Medical Sciences
|